fashion -WSS

fashion

author：explore 2025-10-06 11:31:16 - browse：4591

Anthony Fernandez holds a Wegovy injection, the ALP-1 agonist medication he uses to help curb his food cravings – Obesity medication and science coverage for STAT — A person holds a Wegovy injection pen. Kayana Szymczak for STAT

Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.

Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Medicare would start covering the drug for this usage.

Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Duchenne breakthrough therapy leaves behind pioneering families

WSS

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Four alarming medical procedures we’re glad history forgot

How to save PrEP access — and even expand it

Hepatitis C has a cure — but many Americans still lack access to it

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

entertainment

fashion

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Trial using CRISPR to edit HIV out of cells disappoints

Duchenne breakthrough therapy leaves behind pioneering families

In age of alternative facts, a scholarly course on calling out crap

Medical leaders decry Supreme Court decision on affirmative action

Novavax promises a turnaround & Lilly roils the obesity market

Virginia high school admissions case could be legal follow

Hundreds died while taking an arthritis drug, but nobody alerted patients

Walensky prepares to leave CDC — and Congress — behind

Medical leaders decry Supreme Court decision on affirmative action

knowledge

In age of alternative facts, a scholarly course on calling out crap

Moonlake's readout produced a cash windfall. Risks remain

Malaria cases in Florida and Texas: Here’s what you need to know

Scientific mystery highlights the blind spots in genomics databases

Scientific mystery highlights the blind spots in genomics databases

Insurer loopholes limit power of law against surprise medical bills

focus

focus

focus

focus